| DCAPI1495 |
Aliskiren Hemifumarate
Featured
|
Aliskiren hemifumarate(CGP 60536) is a direct renin inhibitor with IC50 of 1.5 nM. |
|
| DC8106 |
ALLM (Calpain Inhibitor) |
ALLM (Calpain Inhibitor) is cell-permeable, peptide aldehyde inhibitor of calpains and cathepsins. |
|
| DC9830 |
AM-2394
Featured
|
AM-2394 is a potent and selective Glucokinase agonist (GKA), which catalyzes the phosphorylation of glucose to glucose-6-phosphate. |
|
| DC12002 |
AMG 580 |
AMG 580 (AMG580) is a novel potent, selective phosphodiesterase 10A (PDE10A) inhibitor with IC50 of 0.13 nM. |
|
| DC10101 |
AMG-3969
Featured
|
AMG-3969 is a potent glucokinase-glucokinase regulatory protein interaction (GK-GKRP) disruptor with an IC 50 of 4 nM. |
|
| DC11878 |
AMG-579 |
AMG-579 is a potent, selective, CNS penetrant, orally bioavailable PDE10A inhibitor with IC50 of 0.1 nM. |
|
| DC7815 |
Crisaborole(AN-2728)
Featured
|
AN-2728 is a topically administered, boron-containing, anti-inflammatory compound that inhibits PDE4 activity and thereby suppresses the release of TNFalpha, IL-12, IL-23 and other cytokines. |
|
| DC5114 |
Apixaban (BMS 562247-01)
Featured
|
Apixaban is a highly selective, reversible inhibitor of Factor Xa with Ki of 0.08 nM and 0.17 nM in human and rabbit, respectively. |
|
| DC6901 |
Daporinad(FK866,APO866)
Featured
|
APO866 effectively inhibits nicotinamide phosphoribosyltransferase (NMPRTase) with IC50 of 0.09 nM. |
|
| DC7063 |
Apremilast
Featured
|
Apremilast(CC10004) is a novel small molecule inhibitor of PDE4 with an IC50 value of 74 nM. |
|
| DC11809 |
APX-115
Featured
|
APX-115 (Ewha 18278) is a first-in-class, orally active, pan-NADPH oxidase (Nox) inhibitor with Ki of 1.08, 0.57, 0.63 nM for Nox1, Nox2, and Nox4, respectively. |
|
| DC11447 |
Astragaloside IV
Featured
|
Astragaloside IV, an active component isolated from Astragalus membranaceus, suppresses the activation of ERK1/2 and JNK, and downregulates matrix metalloproteases (MMP)-2, (MMP)-9 in MDA-MB-231 breast cancer cells. |
|
| DC11889 |
Atabecestat
Featured
|
Atabecestat (JNJ-54861911, JNJ54861911) is a novel potent, oral beta-secretase (BACE) inhibitor for treatment of Alzheimer's Disease. |
|
| DCAPI1442 |
Atorvastatin Calcium
Featured
|
Atorvastatin Calcium |
|
| DC8799 |
Avanafil(TA-1790)
Featured
|
Avanafil(TA-1790) is a potent and highly selective phosphodiesterase-5(PDE-5) inhibitor(IC50=5.2 nM) for erectile dysfunction; lower selectivity against PDE1, PDE6, and PDE11. |
|
| DC11847 |
AZD2716 |
AZD2716(AZD-2716) is a novel potent, selective, orally bioavailable sPLA2 inhibitor with excellent plasma sPLA2 inhibition (IC50=0.1 nM). |
|
| DC9946 |
Lanabecestat(AZD3293,LY-3314814) |
AZD3293 is a potent and selective orally active, brain-permeable BACE1 inhibitor,currently in development as a potential treatment for early Alzheimer’s disease. |
|
| DC8400 |
AZD3839
Featured
|
AZD3839 is a potent and selective BACE1 inhibitor with Ki of 26.1 nM, about 14-fold selectivity over BACE2. Phase 1. |
|
| DC8060 |
AZD-3988 |
AZD-3988 is a potent and selective diacylglycerol acyltransferase (DGAT-1) inhibitor (IC50 = 0.6 nM). |
|
| DC11723 |
AZD-7986(Brensocatib)
Featured
|
AZD-7986(Brensocatib) is a highly potent, reversible, and selective DPP1 inhibitor with enzyme and cell pIC50 of 8.4. |
|
| DC7371 |
Balicatib
Featured
|
Balicatib(AAE-581) is a potent and selective inhibitor of cathepsin K; 10-100-fold more potent in cell-based enzyme occupancy assays than against cathepsin B, L, and S. |
|
| DC8133 |
Batimastat(BB-94)
Featured
|
Batimastat was used to study the role of MMP in proteolytic release of EGF in human follicular thyroid carcinoma cell line FTC-133. |
|
| DC7782 |
BAY 41-2272 |
Activator of soluble guanylyl cyclase (sGC); acts at a nitric oxide (NO)-independent regulatory site in the sGC α1 subunit. Inhibits platelet aggregation (IC50 = 36 nM) and phenylephrine-induced contractions of rabbit aorta (IC50 = 0.30 μM). Also reduces vascular smooth muscle growth through cAMP- and cGMP-dependent PKA and PKG pathways.. For the detailed information of BAY 41-2272, the solubility of BAY 41-2272 in water, the solubility of BAY 41-2272 in DMSO, the solubility of BAY 41-2272 in PBS buffer, the animal experiment (test) of BAY 41-2272, the cell expriment (test) of BAY 41-2272, the in vivo, in vitro and clinical trial test of BAY 41-2272, the EC50, IC50,and affinity,of BAY 41-2272, Please contact DC Chemicals. |
|
| DC9578 |
Bay 60-7550
Featured
|
Bay 60-7550 is a potent PDE2 inhibitor with IC50 values of 2.0 nM (bovine) and 4.7 nM (human); 50-fold more selective for PDE2 compared to PDE1 and greater than 100-fold selective compared to PDE5, PDE3B, PDE4B, PDE7B, PDE8A, PDE9A, PDE10A, and PDE11A.
|
|
| DC11859 |
BAY85-8501 |
BAY 85-8501 (BAY85-8501) is a potent, selective human neutrophil elastase (HNE) inhibitor with IC50 of 65 pM. |
|
| DC11719 |
BAY-1436032 |
BAY-1436032 (BAY1436032) is a potent, selective, orally available inhibitor of pan-mutant IDH1 with IC50 of 15 nM for both IDH1 R132H and R132C, respectively. |
|
| DC9964 |
BEC hydrochloride
Featured
|
BEC is a boronic acid-based arginine analog that acts as a slow-binding, competitive transition state inhibitor of arginase I and II (Ki = 310 nM for human recombinant type II arginase, pH 7.5). |
|
| DC8160 |
ZGN-440(Beloranib) |
Beloranib is being studied as a first-in-class obesity therapy that demonstrates a unique mechanism of action through methionine aminopeptidase 2 (MetAP2 ) inhibition. |
|
| DC9152 |
Benazepril Hydrochloride |
Benazepril hydrochloride, an angiotensin converting enzyme inhibitor, which is a medication used to treat high blood pressure. |
|
| DC8895 |
benzbromaron
Featured
|
Benzbromarone is a highly effective and well tolerated non-competitive inhibitor of xanthine oxidase, used as an uricosuric agent, used in the treatment of gout. |
|
